All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for HALEON US HOLDINGS LLC · consumer health care company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 19, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 4273
Over-the-Counter Monograph Drug User Fee Amendments
S 2292
Over-the-Counter Monograph Drug User Fee Amendments
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
HR 5166
Financial Services and General Government Appropriations Act, 2026

Lobbying activity 4

Health Issues

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use; H.R.4273/S.2292, Over-the-Counter Monograph Drug User Fee Amendments; H.R.5371, Continuing Appropriations and Extensions Act, 2026.

Taxation/Internal Revenue Code

Issues related to coverage of over-the-counter products with FSAs and HSAs.

Budget/Appropriations

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166).

Trade (domestic/foreign)

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.